<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01619176</url>
  </required_header>
  <id_info>
    <org_study_id>acumicro</org_study_id>
    <nct_id>NCT01619176</nct_id>
  </id_info>
  <brief_title>Acupuncture Study on Rheumatoid Arthritis, Monitoring Microbiome and Blood</brief_title>
  <official_title>Non Inferiority Trial for the Study of Acupuncture on Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese Academy of Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acupuncture is used and recommended by the WHO for the treatment of Rheumatoid Arthritis.&#xD;
&#xD;
      The molecular bases of this recommendation are not known, the investigators want to compare&#xD;
      with the usage of high-throughput molecular technologies the variations occurring in patients&#xD;
      treated with acupuncture and conventional treatment with the ones treated with conventional&#xD;
      treatment only. The investigators observe the variations in blood and in the gut microbiome.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in ACR20-50-70</measure>
    <time_frame>3 weeks and 3 months</time_frame>
    <description>ACR criteria stands for: American College of Rheumatology Criteria. ACR criteria measures improvement in tender or swollen joint counts and improvement in three of the following five parameters:&#xD;
acute phase reactant (such as sedimentation rate) patient assessment physician assessment pain scale disability/functional questionnaire&#xD;
the number indicates the percentage of improvement in tender or swollen joint counts as well percentage improvement in three of the other five criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in SDAI</measure>
    <time_frame>3 weeks and 3 months</time_frame>
    <description>simplified disease activity index SDAI, is the numerical sum of five outcome parameters: tender and swollen joint count (based on a 28-joint assessment), patient and physician global assessment of disease activity [visual analogue scale (VAS) 0-10 cm] and level of C-reactive protein (mg/dl, normal &lt;1 mg/dl)&#xD;
SDAI≦3.3 is the threshold to consider remission</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Acupuncture</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acupuncture plus conventional treatment (methotrexate+leflunomide+non-steroid anti-inflammatory drugs)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional treatment (methotrexate+leflunomide+non-steroid anti-inflammatory drugs)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <description>methotrexate: 7.5mg/week to 15mg/week for 3 months</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>non-steroidal anti-inflammatory drug (NSAID)</intervention_name>
    <description>NSAID: 100mg twice a day for 3 months</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leflunomide</intervention_name>
    <description>leflunomide: 20mg/day for 3 months</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <description>methotrexate: 7.5mg/week to 15mg/week for 3 months</description>
    <arm_group_label>Acupuncture</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>non-steroidal anti-inflammatory drug (NSAID)</intervention_name>
    <description>NSAID: 100mg twice a day for 3 months</description>
    <arm_group_label>Acupuncture</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leflunomide</intervention_name>
    <description>leflunomide: 20mg/day for 3 months</description>
    <arm_group_label>Acupuncture</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Acupuncture</intervention_name>
    <description>30 minutes acupuncture every other day for 3 months.&#xD;
Basic acupoints: Zusanli, st36; Taixi，KI3）; Shenxu, BL23 Additional acupoints due to personal condition: Waiguan，SJ5; Baxie，Ex-UE9;Yinlingquan，(SP9）; Quchi，LI11; Yanglingquan，GB34; Xuehai，SP10; Dazhu，BL11; Dazhui，DU14; Pixu，BL20.</description>
    <arm_group_label>Acupuncture</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The patient should be diagnosed as the first or second stage of rheumatoid Arthritis&#xD;
             (RA) and checked with X ray for additional diagnose.&#xD;
&#xD;
          -  diagnosed for RA according to ACR(1987)&#xD;
&#xD;
          -  the patient should be in the active stage of the disease, defined as：&#xD;
&#xD;
               1. swollen joints &gt;3&#xD;
&#xD;
               2. tender joints &gt; 5&#xD;
&#xD;
               3. any one of the following： (c1.) morning stiffness lasting more than 45 minutes&#xD;
                  (c2.) Erythrocyte Sedimentation Rate (ESR) &gt;= 28mm/h (c3.) C-reactive protein&#xD;
                  (CRP)&gt;= 12mg/L&#xD;
&#xD;
          -  Should not be resistant to MTX nor leflunomide&#xD;
&#xD;
          -  Blood test should satisfy:&#xD;
&#xD;
               1. Hemoglobin (Hb)&gt;=85g/L&#xD;
&#xD;
               2. White cell &gt;=3.5 10+9/L&#xD;
&#xD;
               3. Platelets &gt;= 100 10+9/L&#xD;
&#xD;
               4. Liver function: serum alanine aminotransaminase (ALT), aspartate transaminase&#xD;
                  (AST) and total bilirubin (TBil) should be less than 1.5 times the upper limit of&#xD;
                  normal (ULN)&#xD;
&#xD;
               5. Kidney function: Serum creatinine (Cr) level should be less than ULN.&#xD;
&#xD;
               6. Pregnancy test should be negative&#xD;
&#xD;
          -  should be positive for anti-cyclic citrullinated protein antibodies (anti-CCP).&#xD;
&#xD;
          -  should agree to sign the informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Serious diseases affecting liver, kidney, heart and lung, or diseases related to&#xD;
             hematologic，endocrine and nervous systems. .&#xD;
&#xD;
          -  Be treated by MTX or Leflunomide in the last 3 months.&#xD;
&#xD;
          -  Be treated with cortical hormone （could be intramuscular injection, intravenous&#xD;
             injection or injection to articular cavity） in the last 4 weeks.&#xD;
&#xD;
          -  Be treated with biological agents, such as antagonist of TNF-alpha,IL-6, and CD20 mono&#xD;
             antibody in the last 3 months.&#xD;
&#xD;
          -  Be treated by chronic medicine, such as immunosuppressive agent, Penicillamine,&#xD;
             chloroquine and gold based Disease-modifying antirheumatic drugs (DMARDs) in the last&#xD;
             3 months.&#xD;
&#xD;
          -  Pregnant and breast-feeding woman&#xD;
&#xD;
          -  Having history of serious drug allergy&#xD;
&#xD;
          -  In the acute or chronic phase of infection (such as lung diseases)&#xD;
&#xD;
          -  Easy bleeding patients or patients with local skin infection (only for acupuncture)&#xD;
&#xD;
          -  The patients cannot accept acupuncture (only for acupuncture)&#xD;
&#xD;
          -  Be treated with acupuncture in the past 3 months（only for acupuncture）.&#xD;
&#xD;
          -  No pregnant and breast-feeding woman.&#xD;
&#xD;
          -  No history of serious drug allergy.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine Nardini, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Key laboratory of Computational Biology, Chines Academy of Sciences - Max Planck Institute - Partner Institute for Computational Biology (CAS MPG PICB)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shanghai GuangHua Hospital of integrated traditional and western medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200052</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <study_first_submitted>June 5, 2012</study_first_submitted>
  <study_first_submitted_qc>June 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2012</study_first_posted>
  <last_update_submitted>December 12, 2013</last_update_submitted>
  <last_update_submitted_qc>December 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Sciences</investigator_affiliation>
    <investigator_full_name>Christine Nardini</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>blood</keyword>
  <keyword>gut intestinal microbiome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Inflammatory Agents, Non-Steroidal</mesh_term>
    <mesh_term>Anti-Inflammatory Agents</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Leflunomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

